Patents by Inventor Shoupeng Lai

Shoupeng Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies binding TNFR2 and uses thereof
    Patent number: 11912777
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 27, 2024
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
  • Antibody binding TIM-3 and use thereof
    Patent number: 11807683
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human TIM-3. The present invention further provides a pharmaceutical composition comprising the antibody, as well as uses thereof.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: November 7, 2023
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang
  • Antibodies Binding TNFR2 and Uses Thereof
    Publication number: 20230212302
    Abstract: The present invention relates to a novel antibody and antibody fragment that specifically binds to TNFR2 and to a composition comprising said antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or an antibody fragment thereof and a host cell comprising the same, and to a related use thereof. Besides, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.
    Type: Application
    Filed: December 9, 2022
    Publication date: July 6, 2023
    Applicant: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Huan Lin, Yujia Dang
  • Antibody binding PD-1 and use thereof
    Patent number: 11136394
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human PD-1. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-PD-1 antibody of the invention.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: October 5, 2021
    Assignee: Nanjing Leads Biolabs Co., Ltd.
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang
  • ANTIBODY BINDING TIM-3 AND USE THEREOF
    Publication number: 20210221885
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human TIM-3. The present invention further provides a pharmaceutical composition comprising the antibody, as well as uses thereof.
    Type: Application
    Filed: April 11, 2019
    Publication date: July 22, 2021
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang
  • Antibodies binding LAG-3 and uses thereof
    Patent number: 10844121
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds LAG-3. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-LAG-3 antibody of the invention.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: November 24, 2020
    Assignee: NANJING LEADS BIOLABS CO., LTD
    Inventors: Xiaoqiang Kang, Shoupeng Lai, Xiao Huang, Lijun Zhou
  • ANTIBODY BINDING PD-1 AND USE THEREOF
    Publication number: 20190352402
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human PD-1. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-PD-1 antibody of the invention.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Xiaoqiang KANG, Shoupeng LAI, Xiao HUANG
  • ANTIBODIES BINDING LAG-3 AND USES THEREOF
    Publication number: 20190016800
    Abstract: The present invention provides an isolated monoclonal antibody that specifically binds LAG-3. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 17, 2019
    Inventors: Xiaoqiang KANG, Shoupeng LAI, Xiao HUANG, Lijun ZHOU
  • Method of producing adenoviral vector stocks
    Patent number: 6168941
    Abstract: The present invention provides a method of producing an adenoviral vector stock by providing a culture of cells permissive for growth of adenoviral vectors, wherein the cells are in a medium, culturing the culture under conditions to permit growth of the cells, perfusing fresh medium through the culture for a period of about 1-6 hours, in an amount of at least about two times the volume of medium in the culture, while the density of the cells in the medium is about 40-70% of the density of cells obtained in the medium when the growth of the culture is in the stationary phase, contacting the culture with adenoviral vectors under conditions permissive for the infection of the cells after the perfusion of fresh medium is substantially completed, culturing the infected cells to replicate the adenoviral vectors, and harvesting the infected cells to obtain an adenoviral vector stock.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: January 2, 2001
    Assignee: GenVec, Inc.
    Inventors: Lee-Cheng Liu, Shoupeng Lai